Last reviewed · How we verify
GEn-1124
GEn-1124 is a small molecule that targets the PI3K/AKT pathway.
GEn-1124 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | GEn-1124 |
|---|---|
| Sponsor | GEn1E Lifesciences |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
GEn-1124 works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition can lead to the reduction of tumor growth and the induction of apoptosis in cancer cells.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects (PHASE1)
- A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GEn-1124 CI brief — competitive landscape report
- GEn-1124 updates RSS · CI watch RSS
- GEn1E Lifesciences portfolio CI